Avmacol for Detoxification of Tobacco Carcinogens in Heavy Smokers

Phase 1, randomised, open-label trial in carcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 4 Tablets Per Day of Avmacol at 14 days and Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 8 Tablets Per Day of Avmacol at 14 days. Started Feb 2018; status: completed.